04/06/2017

How FDA Rules Made A $15 Drug Cost $400

Mark L. Baum, Wall Street Journal

The theory is that generic drugs should be less expensive than the original. By the time a generic hits the market, the drug’s patent has expired, allowing competition from companies that didn’t spend millions of dollars to develop it. As more options become available, prices are supposed to drop. But because of quirks in America’s regulatory system, it doesn’t always work out this way.

In 2009 the Food and Drug Administration approved a new version of colchicine, which treats symptoms of gout. Prices rose from 25 cents to $6 per pill. Two years later, the agency approved a new hydroxyprogesterone, which helps prevent premature births. It went from $15 to $400 an injection. In 2014 the FDA approved a generic of the man-made hormone vasopressin. Prices jumped from $11 to $138 for an injection.

What explains the counterintuitive price increases? All these prescription drugs fall under a category known as DESI drugs, named for their inclusion in an FDA program called Drug Efficacy Study Implementation. These drugs came to market before 1962, when getting FDA approval for a drug required proving its safety but not its efficacy. Such drugs, manufactured under expired patents, are used by millions of Americans today.

But once the FDA approves a new-drug application for a DESI drug, the existing drug can be pulled from the market. The “new” drug is treated as a material advance because it underwent testing for safety and efficacy—even though the DESI version was proved safe and effective over decades of actual use. The developer of the new drug may also get a new period of market exclusivity that lasts three years.

This makes little sense. Market exclusivity should let pharmaceutical companies recoup their often enormous investments in genuinely new drugs. Giving monopoly protection for what is essentially a generic version of a DESI drug merely enriches sharp-dealing companies while injuring patients.

Another reason generics often face no competition was described by Scott Gottlieb, President Trump’s nominee for FDA commissioner, in these pages last year. He noted that a generic-drug application can cost as much as $15 million. This high upfront cost is part of why would-be manufacturers of generics often pass on the opportunity to compete against branded drugs with smaller markets. This has allowed many pharmaceutical companies to raise prices with impunity.

[Subscription required.]

Read full article



You May Also Like:

At 100-Day Rally, Trump Marks Accomplishments, Blasts Dems And Media Frank Miles, Fox News

Politico Poll Of White House Press Corps Includes Grand Total Of Three Republicans David Rutz, The Washington Free Beacon

Rumor: Roger Ailes In Talks For New Conservative Network? Allahpundit, Hot Air

Obama Gets Fabulously Rich After Keeping America Poor [Watch] Investor’s Business Daily

Peggy Noonan: Democratic Party ‘Blowing Itself Up’ [Watch] Eddie Scarry, Washington Examiner

Elizabeth Warren: A Factory Of Bad Ideas [Watch] Ken Blackwell, Townhall

Why President Donald Trump’s Tax Plan Is Brilliant Politics And Even Better Economics Jeffrey Tucker, Rare

Yes, The Nation Can Afford Trump’s Tax Cuts Tyler Cowen, New York Post

Twitter Proves New NY Times Columnist Bret Stephens Right About ‘Nasty Left’ Matthew Balan, Mediaite

Poll: Tax Burden Linked To Desire To Move Out Of State Stephanie Marken And Zac Auter, Gallup

Yale College Republicans Host Barbecue Right Next To Hunger Strike Thomas Phippen, Daily Caller

British Students: Clapping And Cheering Excludes Deaf People [Watch] Lukas Mikelionis, Heat Street

Report: Megyn Kelly’s First Interview Is With The Kardashians Katie Jerkovich, The Smokeroom

For More go to the Home Page >>>

Search

Bookshelf

SHARE

Some titles recent, all recommended -

Special Video Feature



Voices From The 2017 International Students For Liberty Conference

In Search Of History

SHARE

Keynesian Economics and the Great Depression

Hillsdale College economics professor Gary Wolfram discusses Keynesian economics and the factors that pulled the national economy out of the Great Depression. The story of World War II shows that government spending may produce activity, but not the prosperity of a truly healthy economy.

 

-- Gary Wolfram, Hillsdale College,

Shadow Stats Snapshot


ShadowStats alternate economic indicators are based on the methodology of noted economist John Williams, specialist in government economic reporting.

  • Unemployment:
    BLS: 4.5%
    Shadow Stats: 22.5%
  • Inflation:
    March Year-to-Year: 2.38% (CPI-U*)
    Shadow Stats: 10.1%

*[cpi-u is the Bureau of Labor Statistics inflation rate for all urban consumers]